Mylan agrees to $465 million settlement over EpiPen classification

(Reuters) - Mylan NV said it agreed to a $465 million settlement with the U.S. Department of Justice related to the manner in which it had improperly classified its EpiPen emergency allergy treatment to pay lower rebates to state health programs.

Mylan agrees to $465 million settlement over EpiPen classification
Read More


Bagikan Berita Ini